These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 15207248)
1. High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients. Iacobellis G; Cipriani R; Gabriele A; Di Mario U; Morano S Cytokine; 2004 Jul; 27(1):25-30. PubMed ID: 15207248 [TBL] [Abstract][Full Text] [Related]
2. The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension. Cipriani R; Sensi M; Gabriele A; Gatti A; Mandosi E; Di Mario U; Morano S Diabetes Nutr Metab; 2004 Apr; 17(2):90-4. PubMed ID: 15244100 [TBL] [Abstract][Full Text] [Related]
3. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Tsai WC; Li YH; Huang YY; Lin CC; Chao TH; Chen JH Clin Sci (Lond); 2005 Jul; 109(1):39-43. PubMed ID: 15740459 [TBL] [Abstract][Full Text] [Related]
4. Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. Cuspidi C; Meani S; Lonati L; Fusi V; Valerio C; Sala C; Magnaghi G; Maisaidi M; Zanchetti A J Hypertens; 2006 Apr; 24(4):647-53. PubMed ID: 16531792 [TBL] [Abstract][Full Text] [Related]
5. [Levels of soluble adhesion molecules among normal and hypertensive type 2 diabetic patients]. Rubio-Guerra AF; Vargas-Robles H; Medina-Santillán R; Escalante-Acosta BA Gac Med Mex; 2008; 144(1):11-4. PubMed ID: 18619052 [TBL] [Abstract][Full Text] [Related]
6. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Mahdy RA; Nada WM; Hadhoud KM; El-Tarhony SA Eye (Lond); 2010 Oct; 24(10):1576-84. PubMed ID: 20508651 [TBL] [Abstract][Full Text] [Related]
7. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients. Nadar S; Blann AD; Lip GY Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942 [TBL] [Abstract][Full Text] [Related]
9. A cross-sectional study of echocardiographic indices, treadmill exercise capacity and microvascular complications in Nigerian patients with hypertension associated with diabetes mellitus. Babalola RO; Ajayi AA Diabet Med; 1992 Dec; 9(10):899-903. PubMed ID: 1478033 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151 [TBL] [Abstract][Full Text] [Related]
11. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937 [TBL] [Abstract][Full Text] [Related]
12. Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. Hildebrandt P; Wachtell K; Dahlöf B; Papademitriou V; Gerdts E; Giles T; Oikarinen L; Tuxen C; Olsen MH; Devereux RB Diabet Med; 2005 Aug; 22(8):1005-11. PubMed ID: 16026365 [TBL] [Abstract][Full Text] [Related]
14. Vascular damage and not hypertension per se influences endothelin-1 plasma levels in patients with non insulin dependent diabetes mellitus. Perfetto F; Tarquini R; de Leonardis V; Piluso A; Becucci A; Anselmi B; Curradi C; Tapparini L; Tarquini B Recenti Prog Med; 1997; 88(7-8):317-20. PubMed ID: 9270291 [TBL] [Abstract][Full Text] [Related]
15. Differences between diabetic and non-diabetic hypertensive patients with first acute non-ST elevation myocardial infarction and predictors of in-hospital complications. Colivicchi F; Mettimano M; Genovesi-Ebert A; Schinzari F; Iantorno M; Melina G; Santini M; Cardillo C; Melina D J Cardiovasc Med (Hagerstown); 2008 Mar; 9(3):267-72. PubMed ID: 18301144 [TBL] [Abstract][Full Text] [Related]
16. Correlation of peripheral arterial blood flow with plasma chemerin and VEGF in diabetic peripheral vascular disease. Zakareia FA Biomark Med; 2012 Feb; 6(1):81-7. PubMed ID: 22296200 [TBL] [Abstract][Full Text] [Related]
17. Associations between cardiac target organ damage and microvascular dysfunction: the role of blood pressure. Strain WD; Chaturvedi N; Hughes A; Nihoyannopoulos P; Bulpitt CJ; Rajkumar C; Shore AC J Hypertens; 2010 May; 28(5):952-8. PubMed ID: 20216092 [TBL] [Abstract][Full Text] [Related]
18. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. Nadar SK; Blann A; Beevers DG; Lip GY J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572 [TBL] [Abstract][Full Text] [Related]
19. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. Kim HW; Ko GJ; Kang YS; Lee MH; Song HK; Kim HK; Cha DR Nephrology (Carlton); 2009 Oct; 14(7):681-8. PubMed ID: 19796028 [TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. Zhang M; Gao X; Bai SJ; Ye XM; Zhang J Eur Rev Med Pharmacol Sci; 2014; 18(9):1307-14. PubMed ID: 24867508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]